(JEN) Jenoptik - Overview
Stock: Imaging, Laser, Optics, Optoelectronics, Mobility
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.00% |
| Yield on Cost 5y | 1.37% |
| Yield CAGR 5y | 11.04% |
| Payout Consistency | 62.1% |
| Payout Ratio | 50.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 37.3% |
| Relative Tail Risk | -14.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.62 |
| Alpha | 16.20 |
| Character TTM | |
|---|---|
| Beta | 0.443 |
| Beta Downside | 0.947 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.85% |
| CAGR/Max DD | -0.11 |
Description: JEN Jenoptik January 19, 2026
Jenoptik AG (XETRA:JEN) is a German-based technology group that supplies advanced photonic and smart-mobility solutions worldwide. Its portfolio spans imaging hardware (microscopes, thermographic cameras, polymer-based camera modules), laser technologies (diode, disk, and diode-pumped disk lasers for ablation, cutting, and range-finding), precision optics (objective lenses, coatings, 3-D measurement systems), and optoelectronic components (LEDs, photodiodes, custom modules). The firm also delivers public-safety products such as speed-enforcement cameras, red-light detection, ANPR systems, and border-security analytics, serving end-markets that include automotive, defense, industrial equipment, semiconductor manufacturing, medical-life sciences, and public-security agencies.
Key recent data points (FY 2023) show revenue of €1.2 bn, an EBIT margin of roughly 7 % and a year-over-year organic growth of 4 % driven primarily by rising demand for laser-based precision manufacturing in the semiconductor and automotive sectors. The photonics market is expected to expand at a CAGR of 7-9 % through 2030, underpinned by the EU’s “Industry 4.0” agenda and stricter vehicle safety regulations, both of which act as tailwinds for Jenoptik’s laser and road-safety product lines. A material-cost sensitivity analysis suggests that a 5 % increase in silicon-based substrate prices could compress margins by 0.3-0.5 percentage points, highlighting the importance of supply-chain diversification.
For a deeper, data-driven assessment of Jenoptik’s valuation and risk profile, you might find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 72.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.31 > 1.0 |
| NWC/Revenue: 18.44% < 20% (prev 29.43%; Δ -10.99% < -1%) |
| CFO/TA 0.10 > 3% & CFO 171.7m > Net Income 72.6m |
| Net Debt (368.6m) to EBITDA (198.3m): 1.86 < 3 |
| Current Ratio: 1.56 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.5m) vs 12m ago 1.43% < -2% |
| Gross Margin: 31.95% > 18% (prev 0.34%; Δ 3161 % > 0.5%) |
| Asset Turnover: 63.08% > 50% (prev 66.18%; Δ -3.10% > 0%) |
| Interest Coverage Ratio: 4.31 > 6 (EBITDA TTM 198.3m / Interest Expense TTM 28.0m) |
Altman Z'' 3.60
| A: 0.12 (Total Current Assets 542.4m - Total Current Liabilities 348.0m) / Total Assets 1.66b |
| B: 0.35 (Retained Earnings 583.3m / Total Assets 1.66b) |
| C: 0.07 (EBIT TTM 120.5m / Avg Total Assets 1.67b) |
| D: 1.15 (Book Value of Equity 780.7m / Total Liabilities 679.4m) |
| Altman-Z'' Score: 3.60 = AA |
Beneish M -3.05
| DSRI: 1.02 (Receivables 191.3m/197.5m, Revenue 1.05b/1.11b) |
| GMI: 1.07 (GM 31.95% / 34.19%) |
| AQI: 0.99 (AQ_t 0.42 / AQ_t-1 0.42) |
| SGI: 0.95 (Revenue 1.05b / 1.11b) |
| TATA: -0.06 (NI 72.6m - CFO 171.7m) / TA 1.66b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of JEN shares?
Over the past week, the price has changed by -1.65%, over one month by +24.27%, over three months by +42.04% and over the past year by +24.47%.
Is JEN a buy, sell or hold?
What are the forecasts/targets for the JEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 26.8 | 2.3% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29 | 10.4% |
JEN Fundamental Data Overview February 02, 2026
P/E Trailing = 22.4034
P/S = 1.448
P/B = 1.3985
P/EG = 2.52
Revenue TTM = 1.05b EUR
EBIT TTM = 120.5m EUR
EBITDA TTM = 198.3m EUR
Long Term Debt = 416.9m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 127.6m EUR (from shortTermDebt, last quarter)
Debt = 419.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 368.6m EUR (from netDebt column, last quarter)
Enterprise Value = 1.89b EUR (1.53b + Debt 419.6m - CCE 59.1m)
Interest Coverage Ratio = 4.31 (Ebit TTM 120.5m / Interest Expense TTM 28.0m)
EV/FCF = 20.70x (Enterprise Value 1.89b / FCF TTM 91.1m)
FCF Yield = 4.83% (FCF TTM 91.1m / Enterprise Value 1.89b)
FCF Margin = 8.65% (FCF TTM 91.1m / Revenue TTM 1.05b)
Net Margin = 6.89% (Net Income TTM 72.6m / Revenue TTM 1.05b)
Gross Margin = 31.95% ((Revenue TTM 1.05b - Cost of Revenue TTM 717.2m) / Revenue TTM)
Gross Margin QoQ = 33.24% (prev 31.48%)
Tobins Q-Ratio = 1.14 (Enterprise Value 1.89b / Total Assets 1.66b)
Interest Expense / Debt = 0.84% (Interest Expense 3.54m / Debt 419.6m)
Taxrate = 27.74% (8.33m / 30.0m)
NOPAT = 87.1m (EBIT 120.5m * (1 - 27.74%))
Current Ratio = 1.56 (Total Current Assets 542.4m / Total Current Liabilities 348.0m)
Debt / Equity = 0.43 (Debt 419.6m / totalStockholderEquity, last quarter 974.9m)
Debt / EBITDA = 1.86 (Net Debt 368.6m / EBITDA 198.3m)
Debt / FCF = 4.04 (Net Debt 368.6m / FCF TTM 91.1m)
Total Stockholder Equity = 964.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.35% (Net Income 72.6m / Total Assets 1.66b)
RoE = 7.53% (Net Income TTM 72.6m / Total Stockholder Equity 964.6m)
RoCE = 8.72% (EBIT 120.5m / Capital Employed (Equity 964.6m + L.T.Debt 416.9m))
RoIC = 8.14% (NOPAT 87.1m / Invested Capital 1.07b)
WACC = 6.05% (E(1.53b)/V(1.95b) * Re(7.55%) + D(419.6m)/V(1.95b) * Rd(0.84%) * (1-Tc(0.28)))
Discount Rate = 7.55% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 81.65 | Cagr: 0.25%
[DCF Debug] Terminal Value 87.65% ; FCFF base≈93.7m ; Y1≈112.7m ; Y5≈181.0m
Fair Price DCF = 81.31 (EV 5.02b - Net Debt 368.6m = Equity 4.65b / Shares 57.2m; r=6.05% [WACC]; 5y FCF grow 21.65% → 2.90% )
EPS Correlation: 17.46 | EPS CAGR: -6.18% | SUE: 0.31 | # QB: 0
Revenue Correlation: 54.78 | Revenue CAGR: 16.98% | SUE: -1.71 | # QB: 0
EPS next Year (2026-12-31): EPS=1.70 | Chg30d=+0.002 | Revisions Net=-1 | Growth EPS=+33.2% | Growth Revenue=+6.4%